These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29404766)

  • 1. Pre-treatment magnetic resonance-based texture features as potential imaging biomarkers for predicting event free survival in anal cancer treated by chemoradiotherapy.
    Hocquelet A; Auriac T; Perier C; Dromain C; Meyer M; Pinaquy JB; Denys A; Trillaud H; Denis De Senneville B; Vendrely V
    Eur Radiol; 2018 Jul; 28(7):2801-2811. PubMed ID: 29404766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoradiotherapy for squamous cell anal carcinoma: a review of prognostic factors.
    Kapacee ZA; Susnerwala S; Wise M; Biswas A; Danwata F; Scott N
    Colorectal Dis; 2016 Nov; 18(11):1080-1086. PubMed ID: 27028038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer.
    Owczarczyk K; Prezzi D; Cascino M; Kozarski R; Gaya A; Siddique M; Cook GJ; Glynne-Jones R; Goh V
    Radiother Oncol; 2019 May; 134():119-126. PubMed ID: 31005205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance based texture parameters as potential imaging biomarkers for predicting long-term survival in locally advanced rectal cancer treated by chemoradiotherapy.
    Jalil O; Afaq A; Ganeshan B; Patel UB; Boone D; Endozo R; Groves A; Sizer B; Arulampalam T
    Colorectal Dis; 2017 Apr; 19(4):349-362. PubMed ID: 27538267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer.
    Kochhar R; Renehan AG; Mullan D; Chakrabarty B; Saunders MP; Carrington BM
    Eur Radiol; 2017 Feb; 27(2):607-617. PubMed ID: 27090113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined PET-CT and MRI for response evaluation in patients with squamous cell anal carcinoma treated with curative-intent chemoradiotherapy.
    Adusumilli P; Elsayed N; Theophanous S; Samuel R; Cooper R; Casanova N; Tolan DJ; Gilbert A; Scarsbrook AF
    Eur Radiol; 2022 Aug; 32(8):5086-5096. PubMed ID: 35274187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China.
    Yuan Y; Xie WH; Li RZ; Chang H; Zeng ZF; Gao YH; Wang QX; Xiao WW
    Cancer Med; 2022 Jan; 11(1):117-127. PubMed ID: 34816622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population-based analysis of the impact of 1 vs. 2 doses of mitomycin on patterns of failure of anal cancer patients treated with concurrent chemoradiotherapy.
    Joseph K; Al Habsi Z; Abraham A; Elangovan A; Ghosh S; Pham T; Shreekumar D; Ramji Z; Paulson K; Tankel K; Usmani N; Severin D; Schiller D; Wong C; Mulder K; Karachiwala H; Doll C; King K; Nijjar T
    Radiother Oncol; 2024 Jul; 196():110219. PubMed ID: 38479443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy.
    Mitra D; Horick NK; Brackett DG; Mouw KW; Hornick JL; Ferrone S; Hong TS; Mamon H; Clark JW; Parikh AR; Allen JN; Ryan DP; Ting DT; Deshpande V; Wo JY
    Oncologist; 2019 Jun; 24(6):e275-e283. PubMed ID: 30755500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoradiotherapy for anal cancer: are we as good as we think?
    Martin D; Rödel C; Fokas E
    Strahlenther Onkol; 2019 May; 195(5):369-373. PubMed ID: 30937508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoradiation versus local excision in treatment of stage I anal squamous cell carcinoma: A population-based analysis.
    Gao X; Goffredo P; Kahl AR; Charlton ME; Weigel RJ; Hassan I
    Eur J Surg Oncol; 2020 Sep; 46(9):1663-1667. PubMed ID: 32199768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insurance status and level of education predict disparities in receipt of treatment and survival for anal squamous cell carcinoma.
    Patel KS; Alhatem A; Gadde U; Ahlawat S; Lambert C; Schwartz RA; Dalla Piazza M
    Cancer Epidemiol; 2020 Aug; 67():101723. PubMed ID: 32408241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Multiagent Chemoradiation in the Management and Prognosis of Anal Squamous Cell Carcinoma.
    Goffredo P; Utria AF; Hrabe JE; Gribovskaja-Rupp I; Kapadia MR; Hassan I
    J Gastrointest Surg; 2019 Apr; 23(4):712-719. PubMed ID: 30644029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT.
    Brown PJ; Zhong J; Frood R; Currie S; Gilbert A; Appelt AL; Sebag-Montefiore D; Scarsbrook A
    Eur J Nucl Med Mol Imaging; 2019 Dec; 46(13):2790-2799. PubMed ID: 31482428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Study of Diffusion-weighted Magnetic Resonance Imaging as an Early Prognostic Biomarker in Chemoradiotherapy in Squamous Cell Carcinomas of the Anus.
    Muirhead R; Bulte D; Cooke R; Chu KY; Durrant L; Goh V; Jacobs C; Ng SM; Strauss VY; Virdee PS; Qi C; Hawkins MA
    Clin Oncol (R Coll Radiol); 2020 Dec; 32(12):874-883. PubMed ID: 33023818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Texture analysis as imaging biomarker of tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance.
    De Cecco CN; Ganeshan B; Ciolina M; Rengo M; Meinel FG; Musio D; De Felice F; Raffetto N; Tombolini V; Laghi A
    Invest Radiol; 2015 Apr; 50(4):239-45. PubMed ID: 25501017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns and Predictors of Relapse Following Radical Chemoradiation Therapy Delivered Using Intensity Modulated Radiation Therapy With a Simultaneous Integrated Boost in Anal Squamous Cell Carcinoma.
    Shakir R; Adams R; Cooper R; Downing A; Geh I; Gilbert D; Jacobs C; Jones C; Lorimer C; Namelo WC; Sebag-Montefiore D; Shaw P; Muirhead R
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):329-339. PubMed ID: 31629837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma.
    Cabel L; Jeannot E; Bieche I; Vacher S; Callens C; Bazire L; Morel A; Bernard-Tessier A; Chemlali W; Schnitzler A; Lièvre A; Otz J; Minsat M; Vincent-Salomon A; Pierga JY; Buecher B; Mariani P; Proudhon C; Bidard FC; Cacheux W
    Clin Cancer Res; 2018 Nov; 24(22):5767-5771. PubMed ID: 30054279
    [No Abstract]   [Full Text] [Related]  

  • 19. Definitive Chemoradiotherapy for Anal Carcinoma: Long-Term Results Based on Consistent Time-to-Event Endpoints.
    De Felice F; Martinetti MT; Orelli S; Bulzonetti N; Musio D; Tombolini V
    Oncology; 2018; 94(1):25-30. PubMed ID: 28918425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG).
    Martin D; Schreckenbach T; Ziegler P; Filmann N; Kalinauskaite G; Tinhofer I; Budach V; Gani C; Zips D; Schimek-Jasch T; Schäfer H; Grosu AL; Thomas E; Krause M; Dapper H; Combs S; Hoffmann C; Stuschke M; Walter F; Belka C; Kurth I; Hadiwikarta WW; Baumann M; Rödel C; Fokas E
    Radiother Oncol; 2022 Feb; 167():233-238. PubMed ID: 34999135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.